Drug intelligence / Profile preview

J54

Development stage: Preclinical
Modality: Small Molecules

Overview

J54 is an investigational **small-molecule** inhibitor of tousled-like kinase 1 that has been studied preclinically as a DNA damage response-targeting anticancer agent. In the provided publication, J54 is described as a TLK1 inhibitor that enhances the synthetic lethal interaction of cisplatin in androgen-insensitive prostate cancer cells by impairing homologous recombination repair, including TLK1-dependent phosphorylation and function of RAD54 family proteins. The available evidence here supports J54 as an early-stage research compound rather than an approved medicine, with development focused on oncology and particularly prostate cancer models.

Other names: TLK1 inhibitor J54TLK-1 inhibitor J54TLK 1 inhibitor J54

Targets

TLK2 (Tousled-like kinase 2)DRD2 (Dopamine D2 Receptor)TLK1 (Tousled like kinase 1)TTK (TTK protein kinase)

Beyond the preview

Go deeper on J54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J54.

Explore the full profile